Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Invested Capital (2016 - 2025)

Historic Invested Capital for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $137.4 million.

  • Gyre Therapeutics' Invested Capital rose 3954.44% to $137.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.4 million, marking a year-over-year increase of 3954.44%. This contributed to the annual value of $98.4 million for FY2024, which is 72169.57% up from last year.
  • Per Gyre Therapeutics' latest filing, its Invested Capital stood at $137.4 million for Q3 2025, which was up 3954.44% from $129.4 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Invested Capital registered a high of $137.4 million during Q3 2025, and its lowest value of -$28.3 million during Q2 2023.
  • Over the past 5 years, Gyre Therapeutics' median Invested Capital value was $79.1 million (recorded in 2022), while the average stood at $62.2 million.
  • Its Invested Capital has fluctuated over the past 5 years, first plummeted by 19582.41% in 2023, then soared by 269994.31% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Invested Capital (Quarter) stood at $41.1 million in 2021, then soared by 75.76% to $72.2 million in 2022, then plummeted by 121.92% to -$15.8 million in 2023, then skyrocketed by 721.7% to $98.4 million in 2024, then surged by 39.65% to $137.4 million in 2025.
  • Its Invested Capital stands at $137.4 million for Q3 2025, versus $129.4 million for Q2 2025 and $104.3 million for Q1 2025.